Destination Medical Center (DMC) is a unique 20-year economic development initiative. The $5.6 billion plan is the largest in Minnesota’s history. With the expansion of Mayo Clinic and DMC growth, Rochester is a global destination for health and wellness and so much more. Rochester, Minnesota is its own special place. It spawned the world-renowned Mayo Clinic, home to those leading the way in life science discoveries and health care innovations. It’s the place people go to get better. Where developers are building an epicenter fueled by economic boom and dramatic growth. Where entrepreneurs come to find their place and discover the next big thing. The Destination Medical Center (DMC) initiative puts you in the middle of it all. | The DMC Initiative serves as a public-private partnership, combining private development by Mayo Clinic and other developers, as well as public funding from the City of Rochester, Olmsted County, and the State of Minnesota to facilitate and support public infrastructure. DMC promotes the City of Rochester, and more broadly, the County, and the State as a world destination medical center, to assist the patients, caregivers, residents, employees, and visitors in fully experiencing Rochester as a premier destination medical center, while providing extended economic development and opportunities for the City, the region, and the State.
Cincinnati Children’s Innovation Ventures
Cincinnati Children’s is a nationally ranked pediatric health system and a recognized leader in both pediatric and adult research. With a legacy of impact spanning more than 90 years—from Albert Sabin’s oral polio vaccine to pioneering discoveries in lung surfactant proteins—we continue to advance science that improves lives. As one of the largest pediatric research institutions in the U.S., we secure $300 million in external research funding annually and play a central role in shaping the future of biomedical innovation. Innovation is embedded in our culture. One-third of our 19,000 employees are engaged in research and innovation across a broad spectrum of life sciences. From breakthrough therapeutic candidates and biotech platforms to diagnostics, medical devices, software, and research tools, our teams are building a pipeline of technologies with the potential for real-world impact. Explore our innovation portfolio and partnership opportunities at cincinnatichildrens.org/innovation-ventures.
CancerFree Biotech
CancerFree Biotech has a patented system to create patient-derived organoids (PDO) using a bionic tumor culture system, which can be used as an avatar to help physicians and patients develop the optimal cancer treatment strategy. The technology uses blood specimens, making it easy and non-intrusive, and has been successful in deriving 130+ different types of solid tumors from real-world cancer patients. CancerFree Biotech is also collaborating with pharmaceutical companies, using their PDO model to predict clinical trial outcomes during the drug development process, potentially helping to validate compounds during the preclinical and clinical trial phases. | CancerFree Biotech has developed a proprietary cancer cell culture system called E.V.A. (Ex Vivo Avatar). E.V.A. combines 3D cell culture scaffolding with AI image recognition to facilitate tumor cell proliferation. Using just 20mL of patient blood, the platform grows tumor cells to generate heterogeneous organoid models that closely mimic the patient’s internal tumor. These models allow pharmaceutical companies to identify the best candidates for clinical trials by validating the efficacy of their drugs in suppressing tumor cells from real patients. | CancerFree Biotech has developed Prometheus Lab AI, a smart-glasses platform that automates R&D lab documentation. With hands-free, real-time workflow capture, Prometheus converts visual input into structured experiment records, reducing manual errors and significantly cutting down on documentation time.
BloodScan Biotech Inc.
BloodScan Biotech Inc. is a biotechnology company dedicated to precision oncology. Founded through technology transfer from a research team at the University of Michigan, BloodScan focuses on advancing innovations in liquid biopsy with the goal of becoming a key global driver in early cancer detection and disease monitoring. Our flagship product, Labyrinth One, is the world’s only liquid biopsy system capable of achieving tissue-biopsy-comparable performance. The system enables stable, fully automated enrichment of circulating tumor cells (CTCs) and delivers ultra-sensitive capabilities for early cancer screening and monitoring. Three Core Advantages: 1. Reliable CTC Isolation and Monitoring in Advanced Cancer – Enables disease monitoring and treatment response assessment in late-stage patients. 2. Tissue-Biopsy-Comparable Performance – Provides accuracy and biological integrity comparable to conventional histopathology. 3. Ultra-Sensitive Early Cancer Screening – Enhances early cancer detection rates to support more precise and timely treatment decisions. Our vision is to establish CTCs as a central pillar of next-generation cancer diagnostics, empowering healthcare systems worldwide to deliver earlier, more precise, and more personalized cancer care. | BloodScan Biotech Inc. Pioneering Liquid Biopsy for Precision Oncology BloodScan Biotech Inc. is a biotechnology company at the forefront of next-generation liquid biopsy technologies, committed to transforming cancer diagnostics through precision medicine. Established in 2023 as a spin-off from the University of Michigan, BloodScan focuses on advancing circulating tumor cell (CTC) isolation to improve early cancer detection, real-time treatment monitoring, and personalized therapeutic decision-making. The heart of BloodScan’s innovation is the Labyrinth One – Automated CTC Enrichment System, a compact, benchtop platform designed for high-throughput, label-free isolation of viable CTCs directly from blood samples. Unlike traditional antibody-based capture technologies, Labyrinth One utilizes microfluidic separation to deliver exceptional purity, recovery, and reproducibility—all within a 15-minute workflow. This allows for seamless integration into both clinical and research laboratory settings, enabling routine use of CTCs for diagnostics and translational oncology research. BloodScan’s mission is to bridge the gap between academic innovation and clinical implementation. Through strategic partnerships with research institutes, oncology centers, and clinical laboratories, the company aims to accelerate the adoption of liquid biopsy technologies and expand access to non-invasive cancer diagnostics that can meaningfully improve patient outcomes.
Biopôle SA
Biopôle Lausanne is one of the largest life sciences campus in Europe, hosting a vibrant community of world-renowned industry players and research institutes, based in Lausanne, Switzerland (www.biopole.ch). It offers a world-class combination of modern infrastructure (134,000 sqm of office/lab space), added value services, an extensive network, innovation and funding programmes, and unparalleled community engagement where members can thrive and bring science to life. Biopôle houses 130+ life sciences companies, including 50 biotech/pharma such as Ferring, Roche, Ichnos, etc. and world-class research organizations (Lausanne University Hospital (CHUV), University of Lausanne (UNIL), the Ludwig Institute for Cancer Research etc.), a life science incubator (StartLab), ready-to-move-in private labs (Superlab), a Digital Health Hub (DH2) enabling the emergence of outstanding innovation for the betterment of healthcare. Join Biopôle.
BioAro
BioAro Inc. is a leading biotechnology company specializing in whole genome sequencing and advanced genetic analysis. With a strong commitment to personalized medicine, BioAro leverages cutting-edge genomic technologies to provide individuals, healthcare professionals, and researchers with comprehensive insights into genetic health, disease predisposition, and personalized wellness strategies. At the core of BioAro’s services is its whole genome sequencing platform, which delivers high-precision genetic data that empowers users to make informed health decisions. The company’s offerings extend beyond raw data by providing advanced interpretation through proprietary bioinformatics pipelines and AI-driven analytics. By transforming complex genetic information into actionable insights, BioAro enables early disease detection, risk assessment, and tailored treatment recommendations. BioAro is dedicated to bridging the gap between genomic science and real-world application by making genetic testing accessible and understandable. Its services cater to a diverse clientele, including individuals interested in proactive health management, clinicians seeking precision medicine solutions, and researchers aiming to advance genetic discoveries. The company also collaborates with pharmaceutical and healthcare organizations to support drug development and personalized therapeutics. With a focus on innovation and data security, BioAro upholds the highest standards of accuracy and confidentiality. Its state-of-the-art sequencing facilities adhere to rigorous quality controls, ensuring reliable results that users can trust. As the demand for personalized medicine grows, BioAro continues to expand its capabilities, staying at the forefront of genomic advancements to improve health outcomes and revolutionize the future of healthcare. | BioAro Inc., established in 2021, is a Canadian biotechnology company headquartered in Calgary, Alberta. The company specializes in precision health, health span, and longevity, integrating genomics, artificial intelligence (AI), and blockchain technologies to deliver personalized healthcare solutions. BioAro’s mission is to revolutionize personalized healthcare through its cutting-edge technologies, including the BioPhenome Lab, BioHealth software solutions, Biospan clinics, and biotech devices. The company’s vision focuses on extending human healthspan by integrating innovative approaches for a healthier future. BioAro operates internationally, with Headoffice in Calgary, Canada; and offices in Dubai, United Arab Emirates; and Almelo, The Netherlands, and United Kingdom reflecting its commitment to making personalized medicine accessible worldwide. BioAro aims to transform healthcare from reactive disease management to proactive health optimization, empowering individuals to take control of their health and well-being. | BioAro Inc. is a Calgary-based precision health biotechnology company advancing real-time, AI-driven multi-omics solutions for personalized medicine. Its PanOmiQ™ platform integrates genomic, epigenomic, pharmacogenomic, microbiome, and clinical data to deliver rapid, scalable insights that support early disease detection, tailored treatment strategies, and predictive healthcare. BioAro’s ecosystem improves clinical decision-making and expands precision medicine markets.
Best Buy Health
Best Buy Health partners with pharmaceutical organizations to enable safe, high-quality, and effective care at home. Through its Current Health solution, Best Buy Health provides an enterprise care-at-home platform, integrated monitoring devices, and robust support services to accelerate and expand access to clinical trials, improve patient experience, and create rich digital data streams for biomarker development. To learn more, please visit https://www.bestbuyhealth.com/care-at-home.
AlphaSense
AlphaSense is a market intelligence and search platform used by the world’s leading companies and financial institutions. Since 2011, our AI-based technology has helped professionals make smarter business decisions by delivering insights from an extensive universe of public and private content—including company filings, event transcripts, expert calls, news, trade journals, and equity research. Our platform is trusted by over 3,500 enterprise customers, including a majority of the S&P 500. Headquartered in New York City, AlphaSense employs over 1,000 people across offices in the U.S., U.K., Germany, Finland, and India. For more information, please visit www.alpha-sense.com. | The world’s most sophisticated companies rely on AlphaSense to remove uncertainty from decision-making. With market intelligence and search built on proven AI, AlphaSense delivers insights that matter from content you can trust. Our universe of public and private content includes equity research, company filings, event transcripts, expert calls, news, trade journals, and clients’ own research content. Founded in 2011, AlphaSense is headquartered in New York City with over 1,000 people across the globe and offices in the U.S., U.K., Finland, India, and Singapore. For more information, please visit www.alpha-sense.com. | AlphaSense is how the world’s most sophisticated companies remove uncertainty from their decision-making. With market intelligence and search built on proven AI, AlphaSense quickly delivers relevant insights from a trustworthy universe of public and private content—including equity research, company filings, event transcripts, expert calls, news, trade journals, and clients’ own research content. Headquartered in New York City, AlphaSense employs over 1,000 people across offices in the U.S., U.K., Finland, India, and Singapore. For more information, please visit www.alpha-sense.com. | AlphaSense is the AI platform redefining market intelligence and workflow orchestration, trusted by thousands of leading organizations to drive faster, more confident decisions in business and finance. The platform combines domain specific AI with a vast content universe of over 500 million premium business documents — including equity research, earnings calls, expert interviews, filings, news, and internal proprietary content. Purpose-built for speed, accuracy, and enterprise-grade security, AlphaSense helps teams extract critical insights, uncover market-moving trends, and automate complex workflows with high quality outputs. With AI solutions like Generative Search, Generative Grid, and Deep Research, AlphaSense delivers the clarity and depth professionals need to navigate complexity and obtain accurate, real-time information quickly. For more information, visit www.alpha-sense.com. | AlphaSense is the AI platform redefining market intelligence and workflow orchestration, trusted by thousands of leading organizations to drive faster, more confident decisions in business and finance. The platform combines domain specific AI with a vast content universe of over 500 million premium business documents. Purpose-built for speed, accuracy, and enterprise-grade security, AlphaSense helps teams extract critical insights, uncover market-moving trends, and automate complex workflows.
ActivInsights
ActivInsights is a Digital Health company. ActivInsights delivers activity, sleep and lifestyle insight to healthcare professionals. We simplify access to real-world patient data with our wearables, connected technologies and secure data infrastructure. With a commitment to improving global public health, ActivInsights is accelerating pharmaceutical drug development, enhancing clinical practice and improving disease management. Our high resolution wearable technologies are designed to be very low burden for long-term continuous wear for participants. We offer a true, unfiltered tri-axial raw data acceleroemeter, the GENEActiv, and a near-real time device, the Activinsights Band for long-term wear. The wearables achieve high compliance and adherence, are cost-effective and enable objective insights into physical activity, gait and mobility, sleep, lifestyle and disease progression. Babies as young as 8 weeks old have worn the devices, up to older adults on the wrist. ActivInsights technologies can be deployed in an array of therapeutic areas to truly understand the patient’s wellbeing in a free living environment, outside of the clinic. We offer seamless integration into existing platforms and can support data processing and analysis services to deliver meaningful digital biomarkers and objective outcome assessments.